联合治疗可减少妇女复发机会小，HER2阳性乳腺肿瘤，研究表明-达纳法伯癌症研究所

在一项2期临床试验中，妇女与小（1级），HER2阳性乳腺肿瘤患者，结合低强度化疗和靶向药物术后有肿瘤复发三年内治疗极不可能的，研究人员在发表了一篇论文，达纳法伯癌症研究所和其他机构的报告今天新英国医学杂志。

The findings may help establish the therapy – which combines the chemotherapy agent paclitaxel and the targeted drug trastuzumab (Herceptin) – as the first standard treatment approach for this group of patients, the authors state。

Many previous studies excluded women with small (less than 2 cm in diameter) HER2-positive breast tumors that hadn’t spread to nearby lymph nodes from clinical trials of trastuzumab, because it wasn’t considered prudent to expose them to an investigational drug, given the relatively low risk that the disease would recur。 Without a single, standard treatment for this group of patients, treatment approaches have varied widely。 (Breast cancers are classified as HER2-positive if their cells have surplus human epidermal growth factor receptors on their surface, making them extra-sensitive to signals to grow and divide。)

“Women with small, HER-2 positive, node-negative [no sign of spread to adjacent lymph nodes] breast tumors have a low, but still significant, risk of recurrence of their disease,” said the study’s senior author, Eric Winer, MD, director of the Breast Oncology Program at the Susan F。 Smith Center for Women’s Cancers at Dana-Farber。 “This study demonstrates that a combination of lower-intensity chemotherapy and trastuzumab – which is associated with fewer side effects than traditional chemotherapy regimens – is an appealing standard of care for this group of patients。”

（注：转载时请注明复诊网）